Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HR positive + HER-2 negative
i
Other names:
ESR1, Era, ESR, NR3A1, ER, ER beta, PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3, ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
;
2099
;
5241
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
PIK3CA mutation + HR positive (16)
PIK3CA mutation + ER positive (10)
HER-2 amplification + RAS wild-type + BRAF wild-type (9)
ESR1 mutation + HR positive (6)
HER-2 positive + HER-2 amplification (4)
RAS wild-type + HER-2 positive (4)
ESR1 wild-type + HR positive (4)
HER-2 amplification + KRAS G12D (3)
BRCA1 mutation + HR positive (3)
BRCA2 mutation + HR positive (3)
ER positive + PIK3CA H1047R (3)
FGFR1 amplification + HR positive (3)
HR positive + BRCA2 mutation (3)
HR-positive + PIK3CA wild-type (3)
PIK3CA exon 20 mutation + HR positive (3)
BRAF wild-type + HER-2 positive (2)
BRCA1 mutation + HER-2 negative (2)
BRCA2 mutation + HER-2 negative (2)
HER-2 S310F + HER-2 amplification (2)
HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)
HER-2 amplification + HER-2 L755S (2)
HER-2 amplification + PD-L1 expression (2)
HER-2 amplification + RAS wild-type (2)
HER-2 expression + HER-2 D769H (2)
HER-2 expression + HER-2 L869R (2)
HER-2 expression + HER-2 amplification (2)
HER-2 expression + TMB-H (2)
RAS wild-type + BRAF wild-type + HER-2 positive (2)
TMB-H + HER-2 positive (2)
AKT1 E17K + HR positive (2)
AKT1 mutation + HR positive (2)
ER Y537S + ER positive (2)
ER positive + TP53 mutation (2)
ER-L (2)
HR negative + BRCA1 mutation (2)
HR negative + BRCA2 mutation (2)
HR positive + BRCA1 mutation (2)
HR positive + MYC amplification (2)
HR positive + TP53 mutation (2)
PIK3CA mutation + ER negative (2)
AR positive + HER-2 amplification (1)
BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)
EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)
EGFR T790M + HER-2 amplification (1)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)
ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)
ER positive + HER-2 D769H + HER-2 V777L (1)
ERBB2 G778A + CCNE1 amplification (1)
ERBB3 mutation + HER-2 amplification (1)
ERBB4 mutation + HER-2 positive (1)
HER-2 amplification + AXL expression (1)
HER-2 amplification + BRAF wild-type (1)
HER-2 amplification + CCNE1 expression (1)
HER-2 amplification + EGFR mutation (1)
HER-2 amplification + ER positive + PGR negative (1)
HER-2 amplification + HER-2 R157W (1)
HER-2 amplification + HER-2 mutation (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 elevation (1)
HER-2 elevation + TMB-H (1)
HER-2 elevation + TMB-L (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HER-2 mutation + HER-2 positive (1)
HER-2 mutation + TMB-H (1)
HER-2 overexpression + CCNE1 amplification (1)
HER-2 overexpression + HER-2 amplification (1)
HER-2 overexpression + KRAS G12C (1)
HER-2 overexpression + KRAS wild-type (1)
HER-2 overexpression + PTEN deletion (1)
HER-2 overexpression + RAS wild-type (1)
HER-2 positive + APC mutation (1)
HER-2 positive + GATA6 amplification (1)
HER-2 positive + MYC amplification (1)
HER-2 positive + TP53 mutation (1)
HER-2 underexpression + CCNE1 amplification (1)
HR positive + HER-2 amplification (1)
HR positive + HER-2 mutation (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS mutation + HER-2 positive (1)
MSI-H + HER-2 amplification (1)
MSI-H/dMMR + HER-2 mutation (1)
NF1 mutation + HER-2 positive (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PIK3C3 mutation + HER-2 positive (1)
PIK3CA H1047R + HER-2 amplification (1)
PIK3CA mutation + HER-2 amplification (1)
PIK3CA mutation + HER-2 positive (1)
PIK3CA mutation + HR positive + HER-2 negative (1)
PIK3R1 mutation + HER-2 positive (1)
POLE E790Q + ERBB2 amplification + TMB-H (1)
RAS wild-type + HER-2 amplification (1)
RAS wild-type + HER-2 overexpression (1)
STAT6 deletion + HER-2 overexpression (1)
AKT1 mutation + ER negative (1)
AKT1 mutation + ER positive (1)
BRCA2 mutation + ER positive (1)
BRCA2 mutation + ER positive + PGR positive (1)
CCND1 mutation + HR positive (1)
CCND2 mutation + HR positive (1)
CCNE1 overexpression + PIK3CA muattion + ER positive (1)
CCNE2 overexpression + PIK3CA mutation + ER positive (1)
CDK4 mutation + HR positive (1)
CDKN1B mutation + HR positive (1)
EGFR mutation + ER positive (1)
ER D538G + ER positive (1)
ER E380Q + ER positive (1)
ER L536H + ER D538G + CCND1 amplification (1)
ER Y537N + ER positive (1)
ER positive + ESR1 mutation + CCND1 amplification (1)
ER positive + ESR1 mutation + FGFR1 amplification (1)
ER positive + ESR1 mutation + PIK3CA mutation (1)
ER positive + ESR1 mutation + TP53 mutation (1)
ER positive + FGFR1 amplification (1)
ER positive + FGFR3 amplification (1)
ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)
ER positive + ZNF217 overexpression (1)
ER underexpression + ER Y537S (1)
ERBB4 H809G + ER positive (1)
ESR1 mutation + PIK3CA mutation + HR positive (1)
FGF19 amplification + ER positive (1)
FGF3 amplification + ER positive (1)
FGF4 amplification + ER positive (1)
FOXA1 expression + ER positive (1)
HR negative + EGFR amplification (1)
HR positive + APOBEC signature (1)
HR positive + AURKA amplification (1)
HR positive + AURKA mutation (1)
HR positive + BRAF V600E (1)
HR positive + BRCA1 mutation + PALB2 mutation (1)
HR positive + BRCA2 mutation + PALB2 mutation (1)
HR positive + BRIP1 amplification (1)
HR positive + CCND1 amplification (1)
HR positive + MYC mutation (1)
HR positive + PIK3CA exon 10 mutation (1)
HR positive + PTEN deletion (1)
HR positive + RAD51C amplification (1)
HR positive + RB1 mutation (1)
HR positive + TMB-H (1)
HR positive + TMB-L (1)
High HDAC6 score + HR positive (1)
KRAS mutation + CDK9 overexpression + HR positive (1)
KRAS mutation + ER expression (1)
KRAS mutation + HR positive (1)
MTOR mutation + HR positive (1)
MYC mutation + ER positive (1)
PIK3CA E542K + HR positive (1)
PIK3CA amplification + PIK3CA mutation + HR positive (1)
PIK3CA exon 7 mutation + HR positive (1)
PIK3CA exon 9 mutation + HR positive (1)
PIK3CA mutation + ESR1 wild-type (1)
PIK3CA wild-type+ ESR1 wild-type (1)
PTEN deletion + ER positive (1)
PTEN mutation + HR positive (1)
TP53 wild-type + ER positive (1)
ER negative + HER-2 positive + PIK3CA H1047R (0)
ER positive + HER-2 negative + ER mutation (0)
HER-2 amplification + KRAS G12C (0)
HER-2 exon 20 mutation + HER-2 amplification (0)
HER-2 positive + FGFR1 amplification (0)
HER-2-H (0)
HR positive + HER-2 negative + TMB-L (0)
PIK3CA E453K + HER-2 positive (0)
PIK3CA E542K + HER-2 positive (0)
PIK3CA E542Q + HER-2 positive (0)
PIK3CA H1047L + HER-2 positive (0)
PIK3CA H1047R + HER-2 positive (0)
PIK3CA N345K + HER-2 positive (0)
PIK3CA amplification + HER-2 positive (0)
AKT1 E17K + CTNNB1 G34R + ER Y537S + MSI-H (0)
ER positive + BRCA1 mutation (0)
ER positive + BRCA2 mutation (0)
PIK3CA mutation + ER negative + PGR positive (0)
PIK3CA mutation + HR positive (16)
PIK3CA mutation + ER positive (10)
HER-2 amplification + RAS wild-type + BRAF wild-type (9)
ESR1 mutation + HR positive (6)
HER-2 positive + HER-2 amplification (4)
RAS wild-type + HER-2 positive (4)
ESR1 wild-type + HR positive (4)
HER-2 amplification + KRAS G12D (3)
BRCA1 mutation + HR positive (3)
BRCA2 mutation + HR positive (3)
ER positive + PIK3CA H1047R (3)
FGFR1 amplification + HR positive (3)
HR positive + BRCA2 mutation (3)
HR-positive + PIK3CA wild-type (3)
PIK3CA exon 20 mutation + HR positive (3)
BRAF wild-type + HER-2 positive (2)
BRCA1 mutation + HER-2 negative (2)
BRCA2 mutation + HER-2 negative (2)
HER-2 S310F + HER-2 amplification (2)
HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)
HER-2 amplification + HER-2 L755S (2)
HER-2 amplification + PD-L1 expression (2)
HER-2 amplification + RAS wild-type (2)
HER-2 expression + HER-2 D769H (2)
HER-2 expression + HER-2 L869R (2)
HER-2 expression + HER-2 amplification (2)
HER-2 expression + TMB-H (2)
RAS wild-type + BRAF wild-type + HER-2 positive (2)
TMB-H + HER-2 positive (2)
AKT1 E17K + HR positive (2)
AKT1 mutation + HR positive (2)
ER Y537S + ER positive (2)
ER positive + TP53 mutation (2)
ER-L (2)
HR negative + BRCA1 mutation (2)
HR negative + BRCA2 mutation (2)
HR positive + BRCA1 mutation (2)
HR positive + MYC amplification (2)
HR positive + TP53 mutation (2)
PIK3CA mutation + ER negative (2)
AR positive + HER-2 amplification (1)
BRCA1 mutation + HER-2 negative + ER positive + PGR positive (1)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)
EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)
EGFR T790M + HER-2 amplification (1)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)
ER negative + HER-2 positive + PGR positive + PIK3CA mutation (1)
ER positive + HER-2 D769H + HER-2 V777L (1)
ERBB2 G778A + CCNE1 amplification (1)
ERBB3 mutation + HER-2 amplification (1)
ERBB4 mutation + HER-2 positive (1)
HER-2 amplification + AXL expression (1)
HER-2 amplification + BRAF wild-type (1)
HER-2 amplification + CCNE1 expression (1)
HER-2 amplification + EGFR mutation (1)
HER-2 amplification + ER positive + PGR negative (1)
HER-2 amplification + HER-2 R157W (1)
HER-2 amplification + HER-2 mutation (1)
HER-2 amplification + KRAS exon 2 wild-type (1)
HER-2 amplification + KRAS wild-type (1)
HER-2 elevation (1)
HER-2 elevation + TMB-H (1)
HER-2 elevation + TMB-L (1)
HER-2 exon 20 insertion + TMB-L + PD-L1 negative (1)
HER-2 mutation + HER-2 positive (1)
HER-2 mutation + TMB-H (1)
HER-2 overexpression + CCNE1 amplification (1)
HER-2 overexpression + HER-2 amplification (1)
HER-2 overexpression + KRAS G12C (1)
HER-2 overexpression + KRAS wild-type (1)
HER-2 overexpression + PTEN deletion (1)
HER-2 overexpression + RAS wild-type (1)
HER-2 positive + APC mutation (1)
HER-2 positive + GATA6 amplification (1)
HER-2 positive + MYC amplification (1)
HER-2 positive + TP53 mutation (1)
HER-2 underexpression + CCNE1 amplification (1)
HR positive + HER-2 amplification (1)
HR positive + HER-2 mutation (1)
KRAS G12D + HER-2 amplification + TMB-H (1)
KRAS mutation + HER-2 positive (1)
MSI-H + HER-2 amplification (1)
MSI-H/dMMR + HER-2 mutation (1)
NF1 mutation + HER-2 positive (1)
PD-L1 overexpression + HER-2 exon 20 insertion (1)
PIK3C3 mutation + HER-2 positive (1)
PIK3CA H1047R + HER-2 amplification (1)
PIK3CA mutation + HER-2 amplification (1)
PIK3CA mutation + HER-2 positive (1)
PIK3CA mutation + HR positive + HER-2 negative (1)
PIK3R1 mutation + HER-2 positive (1)
POLE E790Q + ERBB2 amplification + TMB-H (1)
RAS wild-type + HER-2 amplification (1)
RAS wild-type + HER-2 overexpression (1)
STAT6 deletion + HER-2 overexpression (1)
AKT1 mutation + ER negative (1)
AKT1 mutation + ER positive (1)
BRCA2 mutation + ER positive (1)
BRCA2 mutation + ER positive + PGR positive (1)
CCND1 mutation + HR positive (1)
CCND2 mutation + HR positive (1)
CCNE1 overexpression + PIK3CA muattion + ER positive (1)
CCNE2 overexpression + PIK3CA mutation + ER positive (1)
CDK4 mutation + HR positive (1)
CDKN1B mutation + HR positive (1)
EGFR mutation + ER positive (1)
ER D538G + ER positive (1)
ER E380Q + ER positive (1)
ER L536H + ER D538G + CCND1 amplification (1)
ER Y537N + ER positive (1)
ER positive + ESR1 mutation + CCND1 amplification (1)
ER positive + ESR1 mutation + FGFR1 amplification (1)
ER positive + ESR1 mutation + PIK3CA mutation (1)
ER positive + ESR1 mutation + TP53 mutation (1)
ER positive + FGFR1 amplification (1)
ER positive + FGFR3 amplification (1)
ER positive + MLH1 1835del3 + MSI-H/dMMR + TMB-H (1)
ER positive + ZNF217 overexpression (1)
ER underexpression + ER Y537S (1)
ERBB4 H809G + ER positive (1)
ESR1 mutation + PIK3CA mutation + HR positive (1)
FGF19 amplification + ER positive (1)
FGF3 amplification + ER positive (1)
FGF4 amplification + ER positive (1)
FOXA1 expression + ER positive (1)
HR negative + EGFR amplification (1)
HR positive + APOBEC signature (1)
HR positive + AURKA amplification (1)
HR positive + AURKA mutation (1)
HR positive + BRAF V600E (1)
HR positive + BRCA1 mutation + PALB2 mutation (1)
HR positive + BRCA2 mutation + PALB2 mutation (1)
HR positive + BRIP1 amplification (1)
HR positive + CCND1 amplification (1)
HR positive + MYC mutation (1)
HR positive + PIK3CA exon 10 mutation (1)
HR positive + PTEN deletion (1)
HR positive + RAD51C amplification (1)
HR positive + RB1 mutation (1)
HR positive + TMB-H (1)
HR positive + TMB-L (1)
High HDAC6 score + HR positive (1)
KRAS mutation + CDK9 overexpression + HR positive (1)
KRAS mutation + ER expression (1)
KRAS mutation + HR positive (1)
MTOR mutation + HR positive (1)
MYC mutation + ER positive (1)
PIK3CA E542K + HR positive (1)
PIK3CA amplification + PIK3CA mutation + HR positive (1)
PIK3CA exon 7 mutation + HR positive (1)
PIK3CA exon 9 mutation + HR positive (1)
PIK3CA mutation + ESR1 wild-type (1)
PIK3CA wild-type+ ESR1 wild-type (1)
PTEN deletion + ER positive (1)
PTEN mutation + HR positive (1)
TP53 wild-type + ER positive (1)
ER negative + HER-2 positive + PIK3CA H1047R (0)
ER positive + HER-2 negative + ER mutation (0)
HER-2 amplification + KRAS G12C (0)
HER-2 exon 20 mutation + HER-2 amplification (0)
HER-2 positive + FGFR1 amplification (0)
HER-2-H (0)
HR positive + HER-2 negative + TMB-L (0)
PIK3CA E453K + HER-2 positive (0)
PIK3CA E542K + HER-2 positive (0)
PIK3CA E542Q + HER-2 positive (0)
PIK3CA H1047L + HER-2 positive (0)
PIK3CA H1047R + HER-2 positive (0)
PIK3CA N345K + HER-2 positive (0)
PIK3CA amplification + HER-2 positive (0)
AKT1 E17K + CTNNB1 G34R + ER Y537S + MSI-H (0)
ER positive + BRCA1 mutation (0)
ER positive + BRCA2 mutation (0)
PIK3CA mutation + ER negative + PGR positive (0)
›
Associations
(5)
News
Trials
Search handles
@DrSGraff
@Dr_Ivanoncologo
@ErikaHamilton9
@FilippoMontemu1
@GlopesMd
@MLPOncoData
@NCIDirector
@OncoThor
@VivekSubbiah
@aftimosp
@cczielinski
@iBreastSurgeon
@maryam_lustberg
@matteolambe
@prat_aleix
@teamoncology
Search handles
@DrSGraff
@Dr_Ivanoncologo
@ErikaHamilton9
@FilippoMontemu1
@GlopesMd
@MLPOncoData
@NCIDirector
@OncoThor
@VivekSubbiah
@aftimosp
@cczielinski
@iBreastSurgeon
@maryam_lustberg
@matteolambe
@prat_aleix
@teamoncology
Filter by
Latest
11ms
Breast Cancer Research: Final results of TROPiCS-02 reported at #ASCO23. Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer Read more ➡️ https://t.co/mBMz5ZnZox CC: @DFCI_BreastOnc @STolaney1 (@DanaFarberNews)
11 months ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
11ms
Presented at #ASCO23 very important data from the #SOFT trial to increase our understanding of the biology of hormone receptor-positive/HER2-negative #BreastCancer in premenopausal women: congratulations @LoiSher @etop_ibcsg et all! @OncoAlert (@matteolambe)
11 months ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
11ms
The addition of ribociclib to endocrine therapy extended invasive DFS for patients with hormone receptor-positive, HER2-negative early-stage breast cancer #ASCO23 @UCLAJCCC @MDAndersonNews @NovartisCancer @DrDebuTripathy #Kisqali #NATALEE https://t.co/je2JJdsf0t (@HemOncToday)
11 months ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Kisqali (ribociclib)
11ms
Lerociclib/Fulvestrant May Reduce Risk of Disease Progression in Advanced HR-Positive/HER2-Negative Breast Cancer https://t.co/TWzsHInxAr @ASCO #ASCO23 @glopesMD (@GlopesMd)
11 months ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
fulvestrant • lerociclib (G1T38)
almost1year
Watch Dr. Jennifer Litton discuss treatment recommendations and supporting research on use of endocrine therapy and CDK4/6 inhibitors for both metastatic and high-risk, early HR positive/HER2 negative breast cancer. https://t.co/b2WPpFRNbp @MDEdgeTweets @JenniferLitton #EndCancer (@MDAndersonNews)
almost 1 year ago
Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
1year
New📰in Current Treatment Options in Oncology from Dr. Erica Mayers and Dr. Jamie Brett discussing new developments in systemic management for high-risk early-stage hormone-receptor-positive, HER2-negative breast cancer. @elmayermd #breastcancer 👉https://t.co/kJMnlxuaxX (@DFCI_BreastOnc)
1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
1year
also, stay tuned for this mini-oral from my group! 3MO - HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): a correlative analysis from SOLTI-TOT-HER3 trial (ID 48) @_SOLTI… https://t.co/rfUtZabNh8 (@prat_aleix)
1 year ago
HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HER-2 positive • HR positive • HER-2 negative • HER-2 expression • ERBB3 expression • HR positive + HER-2 negative
|
patritumab deruxtecan (U3-1402)
1year
In this #OpenAccess review, @laura_huppert et al discuss current and emerging therapies for both early-stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data 🔗 https://t.co/TS4avPLsog @Idossa_MD @hoperugo (@CAonline)
1 year ago
Review • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
1year
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: results from the prospective BioItaLEE trial https://t.co/1qdrIoP8b8 So proud to be part of this! TKI is a very promising, low cost biomarker! (@FilippoMontemu1)
1 year ago
Clinical • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Kisqali (ribociclib) • letrozole
over1year
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial https://t.co/EbRGcGlZVr (@MLPOncoData)
over 1 year ago
Clinical • P3 data: top line
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Verzenio (abemaciclib)
over1year
Be sure to read the full article here! Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE) #BrownJC https://t.co/7CicovKBIW (@DrSGraff)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Verzenio (abemaciclib)
over1year
At an @theNCI town hall with staff this morning, I shared that I’ve been very recently diagnosed with hormone receptor-positive, HER2-negative early #BreastCancer. My prognosis is very favorable. To anyone with cancer today: I am truly in this together with you. #bcsm (@NCIDirector)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
over1year
It is a pleasure to share with you the poster LACOG 0221 - BRAVE - Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil, presented in the @SABCSSanAntonio in Texas, USA, by Dr. @GWerutsky (@LACOG_group)
over 1 year ago
Clinical • Real-world evidence
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
over1year
A CDK4/6 inhibitor plus endocrine therapy combination extended PFS by nearly a year compared with #chemotherapy as first-line treatment for premenopausal patients with aggressive, HR-positive/HER2-negative advanced #breastcancer. #SABCS22. https://t.co/06hfUVhUI7 @VKaklamani (@MedpageOnco)
over 1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
over1year
.@YAbdouMD and colleagues reported at #SABCS22 that Non-Hispanic Black women with hormone receptor (HR)-positive/HER2-negative, lymph node-positive breast cancer had worse outcomes compared to non-Hispanic whites, Asians, and Hispanics. https://t.co/YYBy4EKu2f (@UNC_Lineberger)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
over1year
Black women with hormone receptor-positive/HER2-negative breast cancer may have worse outcomes than their peers despite similar genetic risk scores, according to a new analysis of the RxPONDER trial presented at #SABCS22. Learn more: https://t.co/p7Fa9ImYqW @YAbdouMD (@AACR)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
over1year
Something to watch out amidst surge of Abema. (wishing it away since retro analysis..remember, a case report led to id of pandemic) Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Re… https://t.co/3cl2LQtI5Z (@iBreastSurgeon)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Verzenio (abemaciclib)
over1year
P5-02-31 Thursday @SABCSSanAntonio Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial Presenter: @fara_bm (@prat_aleix)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
patritumab deruxtecan (U3-1402)
over1year
P1-13-16Tuesday @SABCSSanAntonio Dissecting the biological activity of different CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer Presenter: @fara_bm (@prat_aleix)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
over1year
P3-06-02 Wednesday @SABCSSanAntonio TATEN TRIAL (SOLTI-1716) Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC): interim analysis Presenter: @Prat2Prat2022 ()
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Prosigna™ Breast Cancer Prognostic Gene Signature Assay
|
Keytruda (pembrolizumab) • paclitaxel
over1year
LISTEN: @hoperugo @UCSFHospitals on the latest results from the TROPiCS-02 trial showing Trodelvy improves overall survival compared to chemotherapy in metastatic, hormone receptor-positive, HER2-negative breast cancer. https://t.co/aOjC27RsWV via @Breastcancerorg #bcsm (@UCSFCancer)
over 1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Trodelvy (sacituzumab govitecan-hziy)
over1year
DARE study #bcsm DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer - Full Text View - https://t.co/WcqCirJpp7 (@maryam_lustberg)
over 1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
over1year
Trodelvy significantly improved overall survival for patients with HR-positive/HER2 negative #metastaticbreastcancer who are endocrine therapy-resistant, a population with limited treatment options, explained @hoperugo from @UCSFCancer at #ESMO22. #BCSM https://t.co/FroXdAGvub (@cure_today)
over 1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Trodelvy (sacituzumab govitecan-hziy)
over1year
Dr Stephen Johnston provides past 12 months new data for hormone receptor positive HER2 negative metastatic breast cancer at #ESMO22 (@teamoncology)
over 1 year ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
over1year
Trodelvy demonstrated a clinically meaningful improvement of 3.2 monthin overall survival compared to physician choice chemotherapy. A new treatment choice for hormone receptor-positive HER2 negative metastatic breast cancer. Exciring. https://t.co/LAzeObZBD2 (@teamoncology)
over 1 year ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Trodelvy (sacituzumab govitecan-hziy)
almost2years
Up next is Dr. Tufia Haddad with updates on hormone receptor positive and HER2-negative breast cancer. Man, there is a lot of exciting stuff going on in breast cancer therapy these days! I have such respect for oncologists in general practice. There is so much data out there… 😮 (@OncoThor)
almost 2 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
almost2years
CDK4/6 inhibition + endocrine therapy extends post-progression PFS in HR-positive/HER2-negative metastatic #BreastCancer. https://t.co/mgm853Emiu @KalinskyKevin @claudine_isaacs @LombardiCancer @WinshipAtEmory #ASCO22 #ASCODailyNews #BCSM (@ASCO)
almost 2 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
almost2years
15.8 months improved OS 1st line for premenopausal #HR #bcsm patients w/ the addition of ribociclib Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer - The ASCO Post https://t.co/KteUaTVvOr (@ErikaHamilton9)
almost 2 years ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Kisqali (ribociclib)
2years
After a bumpy start, CDK4/6 inhibitors have started to gain traction in early hormone receptor (HR)-positive/HER2-negative breast cancer, reported @stolaney1, MD, at #miamibreast. By @CBankheadMPT @gotoPER https://t.co/hPZ9juhM7P (@MedpageOnco)
2 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
2years
"Study of #Samuraciclib a first-in-class, oral, selective inhibitor of #CDK7, in combination with fulvestrant in patients with advanced hormone receptor-positive, HER2-negative Breast Cancer" interesante revisión de la Dra. Denisse Lee #SABCS @FUCAMM @OncoAlert @BCTrials (@Dr_Ivanoncologo)
2 years ago
Clinical • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • CDK7 (Cyclin Dependent Kinase 7)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
samuraciclib (CT7001)
2years
Michael Gnant on HR-Positive HER2-Negative Early Breast Cancer Trial Results With Palbociclib Treatment - The ASCO Post https://t.co/WdlHwzMSdX @ABCSGVienna @elmayermd @AngieDemichele (@MichaelGnant)
2 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
Ibrance (palbociclib)
over2years
Lisa A. Carey, MD, on HR-Positive and HER2-Negative Advanced Breast Cancer: Overall Survival by Subtype Across Three MONALEESA Studies https://t.co/MVhx0Jj54k #bcsm #SABCS21 #oncology #cancer @DrLisaCarey @UNC_Lineberger (@ASCOPost)
over 2 years ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
over2years
Particularly, in the hormone receptor positive/HER2 negative breast cancer subtype. Among Black women, they had almost double the recurrence risk of white women. This is consistent from earlier reports in the @folopade research team. (@tigerlilycares)
over 2 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
over2years
Happening at 11AM in Hall 3: Dr. Gradishar & @BCJoyceO: Study of samuraciclib, a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer. #SABCS21 #oncology #SABCS2021 (@IDEOOncology)
over 2 years ago
Clinical • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • CDK7 (Cyclin Dependent Kinase 7)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
samuraciclib (CT7001)
over2years
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a @FDAOncology pooled analysis https://t.co/PNFGTQlQCc #bcsm @OncoAlert (@aftimosp)
over 2 years ago
Retrospective data
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
over2years
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial | Nature Medicine https://t.co/fuawAaSfVj (@VivekSubbiah)
over 2 years ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
AiRuiKang (dalpiciclib)
over2years
Congratulations to @mfrimawi for publishing his research on the management of hormone receptor-positive, HER2-negative #MetastaticBreastCancer in the Breast Cancer Research and Treatment Journal. #Oncology #OncTwitter @StLukesHealthMD @BCMCancerCenter https://t.co/wdvhJNtF25 (@ProfAMThompson)
over 2 years ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
over2years
🚨⭐️Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor + fulvestrant: @FDAOncology pooled analysis #BCSM @drjennifergao https://t.co/Lr5r3ZFwMy (@VivekSubbiah)
over 2 years ago
Retrospective data
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
over2years
🚨@myESMO daily reporter outlines CDK4/6 inhibitors & MONALEESA trial by @MDAndersonNews legend Dr. Hortobagyi that has led to a paradigm shift in the treatment of HR-positive/HER2-negative #aBC, @OncoAlert #ESMO21 Editorial by @CarmenCriscit 👉 https://t.co/yn0I19kChC #bcsm (@VivekSubbiah)
over 2 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
almost3years
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial https://t.co/0Wwh5q1RcO (@VivekSubbiah)
almost 3 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Ibrance (palbociclib)
over3years
News: Phase 2 data reported by @stolaney1 (@DanaFarber) and colleagues in @JAMAOnc do not support the addition of #pembrolizumab to #eribulin for HR-positive, HER2-negative metastatic #BreastCancer #bcsm https://t.co/J78O1jsjcs (@MM_Oncology)
over 3 years ago
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Keytruda (pembrolizumab) • Halaven (eribulin mesylate)
over3years
#ESMO20 news: Combining #palbociclib with adjuvant endocrine therapy did not benefit HR-positive, HER2-negative, early #BreastCancer patients in the #PALLAS trial presented by @elmayermd (@danafarber) at #ESMO2020 #BCSM https://t.co/I6XXc4sj1f (@MM_Oncology)
over 3 years ago
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative • HR positive + HER-2 negative
|
Ibrance (palbociclib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login